IMPORTANCE As an effective drug for the treatment of carbapenem-resistant Klebsiella pneumoniae , ceftazidime-avibactam (CZA) began to develop resistance in recent years and showed an increasing trend.
← all excerpts
A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated <i>Klebsiella pneumoniae</i>.
1
—
—